Subcutaneously administered repronex®  in oligoovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotropin treatment

Nichols, Jason J.; Knochenhauer, Eric S.; Fein, Seymour; Nardi, Ronald V.; Marshall, Dennis C.

doi:10.1016/s0015-0282(01)01856-8

Cited by 8 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hCG trigger may be given as a subcutaneous (SC) or intramuscular (IM) injection. IM and SC administrations result in similar serum hCG levels in women with BMI < 30 [ 89 , 90 ]. Data from the IVF literature suggests that IM hCG injection is preferred over SC injection in obese women given significantly lower serum levels in the SC group [ 91 ].…”

Section: How Do Cycle Factors Affect Pregnancy Outcomes?mentioning

confidence: 99%

Predictive factors for intrauterine insemination outcomes: a review

Starosta

Gordon

Hornstein

2020

Fertil Res and Pract

View full text Add to dashboard Cite

Purpose Intrauterine insemination (IUI) is a frequently utilized method of assisted reproduction for patients with mild male factor infertility, anovulation, endometriosis, and unexplained infertility. The purpose of this review is to discuss factors that affect IUI outcomes, including infertility diagnosis, semen parameters, and stimulation regimens. Methods We reviewed the published literature to evaluate how patient and cycle specific factors affect IUI outcomes, specifically clinical pregnancy rate, live birth rate, spontaneous abortion rate and multiple pregnancy rate. Results Most data support IUI for men with a total motile count > 5 million and post-wash sperm count > 1 million. High sperm DNA fragmentation does not consistently affect pregnancy rates in IUI cycles. Advancing maternal and paternal age negatively impact pregnancy rates. Paternal obesity contributes to infertility while elevated maternal BMI increases medication requirements without impacting pregnancy outcomes. For ovulation induction, letrozole and clomiphene citrate result in similar pregnancy outcomes and are recommended over gonadotropins given increased risk for multiple pregnancies with gonadotropins. Letrozole is preferred for obese women with polycystic ovary syndrome. IUI is most effective for women with ovulatory dysfunction and unexplained infertility, and least effective for women with tubal factor and stage III-IV endometriosis. Outcomes are similar when IUI is performed with ovulation trigger or spontaneous ovulatory surge, and ovulation may be monitored by urine or serum. Most pregnancies occur within the first four IUI cycles, after which in vitro fertilization should be considered. Conclusions Providers recommending IUI for treatment of infertility should take into account all of these factors when evaluating patients and making treatment recommendations.

show abstract

Section: How Do Cycle Factors Affect Pregnancy Outcomes?mentioning

confidence: 99%

Predictive factors for intrauterine insemination outcomes: a review

Starosta

Gordon

Hornstein

2020

Fertil Res and Pract

View full text Add to dashboard Cite

show abstract

“…Two previous studies found no differences in adverse effects between subcutaneous and intramuscular injections of ART drugs [Nichols et al 2001;Out et al 1997]. In contrast, a third study found that subcutaneous injections allowed for self-administration and reduced injection pain [Kapplan et al 2000].…”

Section: Discussionmentioning

confidence: 99%

“…Most (414 articles), analyze the long-term safety and adverse effects of gonadotropins. Only 29 articles analyzed the short-term adverse effects of these drugs, focusing mostly on patient [Gibreel and Bhattacharya S 2009;Somkuti et al 2006;Gocial et al 2000] and nurse [Porter et al 2008], satisfaction and administration comfort, as well as with drug convenience [Nahuis et al 2009;Kettel et al 2004;Pang et al 2003;Platteau et al 2003], drug tolerance [Rama et al 2008;Christianson et al 2007], incidence of allergic reactions [Harrison et al 2000;Redfearn et al 1995;Kinoshita et al 1999;Harika et al 1994;Dore et al 1994], and local tolerability [Diedrich 2002;Feigenbaum et al 2001;Alviggi et al 2007;Giles et al 2004;Nichols et al 2001;Engmann et al 1998;Olivennes et al 2000;Van Hooren et al 2001] associated with the drug presentation or means of administration. Only three articles describe the general effects profile [Gillies et al 2000;Banz et al 2002;Goa and Wagstaff 1998].…”

Section: Introductionmentioning

confidence: 99%

Drug tolerability in assisted reproduction techniques: a longitudinal study

Heredia¹,

Tenías²,

Sánchez³

et al. 2012

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

A longitudinal, observational prospective panel cohort study of 61 patients lasting one year was undertaken. Explanatory variables included sociodemographic factors along with factors related to the underlying pathology as well as the protocol used and the type of treatment received. These variables were analyzed both individually and in combination to account for confounding effects and model interactions. A generalized estimating equation (GEE) model was constructed for each adverse effect. Associations were calculated as odds ratios (OR). Confounding variables related to drug tolerability were identified. Follitropin-alpha and cetrorelix exhibited the poorest safety profile. With respect to local adverse drug reactions (ADEs), the results obtained in our study point to statistically significant tolerability improvements for menotropin when administered in insemination. For gastrointestinal ADEs, ganirelix was the drug that showed the highest tolerability in in vitro treatments whereas follitropin-alpha showed the lowest tolerability in insemination treatments. Diverse factors related to assisted reproduction techniques (ART) influence the incidence of adverse effects. Each drug has a different safety profile with possible interactions depending on the type of assisted reproduction therapy used.

show abstract

“…After screening the full texts, a total of 318 papers were excluded as they did not meet the eligibility criteria. Finally, 34 papers were included in this systematic review (Aghssa et al, 2008(Aghssa et al, , 2012Alviggi et al, 2007;Bergh et al, 2012;Dickey et al, 2002Dickey et al, , 2003European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone, 2002;European and Middle East Orgalutran Study Group, 2001;Germond et al, 2002;Gocial et al, 2000;Greco et al, 2005;Hovatta et al, 2009;Kang et al, 2011;Kettel et al, 2004;Keye et al, 2005;Lan et al, 2008;Lavery et al, 2008;Lockwood et al, 2014;Ng et al, 2003Ng et al, , 2007Nichols et al, 2001;Out et al, 1997;Pang et al, 2003;Porter et al, 2008;Pouly et al, 1996;Schoolcraft et al, 2000;Simunic et al, 2007;Somkuti et al, 2006;Tomic et al, 2011Tomic et al, , 2015Utsunomiya et al, 2012;Verhoeff et al, 1997;Welcker et al, 2010;Zorn et al, 2001). One paper actually reported on two separate studies (Porter et al, 2008).…”

Section: Study Selectionmentioning

confidence: 99%

“…Recruitment took place in various regions around the world (mostly Europe; n = 18/35; Alviggi et al, 2007;Bergh et al, 2012;European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone, 2002;European and Middle East Orgalutran Study Group, 2001;Germond et al, 2002;Greco et al, 2005;Hovatta et al, 2009;Lavery et al, 2008;Lockwood et al, 2014;Out et al, 1997;Porter et al, 2008 [German pilot study]; Pouly et al, 1996;Simunic et al, 2007;Tomic et al, 2011Tomic et al, , 2015Verhoeff et al, 1997;Welcker et al, 2010;Zorn et al, 2001). Most studies had a multi-clinic setting (n = 18), including six studies that recruited patients from different countries (Bergh et al, 2012;European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone, 2002;European and Middle East Orgalutran Study Group, 2001;Hovatta et al, 2009;Lockwood et al, 2014;Out et al, 1997) and 12 from one country (Alviggi et al, 2007;Dickey et al, 2002Dickey et al, , 2003Gocial et al, 2000;Kettel et al, 2004;Keye et al, 2005;Nichols et al, 2001;Pang et al, 2003;Somkuti et al, 2006;Utsunomiya et al, 2012;Verhoeff et al, 1997;…”

Section: Study Selectionmentioning

confidence: 99%